Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S.

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $63.24 which represents a slight increase of $1.00 or 1.61% from the prior close of $62.24. The stock opened at $62.5 and touched a low ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...